ADME WorkBench

The shortest path from chemical properties and preclinical data to human ADME prediction

ADME Workbench is a versatile software application providing flexible, robust pharmacokinetic modeling by integrating state-of-the-art absorption, distribution, metabolism and excretion methods. Designed for research applications in toxicology, pharmacology and biotechnology, ADME Workbench supports pharmacokinetic prediction from in vitro and/or in vivo data for drugs and environmental

ADME WorkBench

Need More information?

acslX

The modeling, execution, and analysis environment for continuous dynamic systems and processes.

As the descendant of the ACSL family of modeling and simulation tools, originally developed in 1974 and now widely used for PBPK and PK/PD modeling, acslX supports both textual and graphical languages for specifying complex biological models, and a Matlab-like scripting language for specification of parameter estimation, sensitivity analysis, Monte-Carlo, or Markov-Chain Monte Carlo analyses. For computationally intensive problems, acslX includes support for cluster/grid computing.  Data integration capabilities with Microsoft Excel and Access are provided, and a PBPK/PK/PD toolkit is also available which includes linear and nonlinear PBPK models of various organs, exposure models for inhalation, oral and dermal exposures, and a variety of PD dose response models.

acslX

Need More information?

Following several months of product/market analysis and careful leadership consideration, effective November 24, 2015
The AEgis Technologies Group will cease further development all variants of our ACSL/X and ADME products.
The last day that these products, and annual maintenance were available for purchase was November 24, 2015.
The Sale of New Licenses has Ended as of November 24, 2015.
All purchases made until said date will be honored in their entirety. We will also be offering for purchase a ‘forever’ license, and are open to discussion of source code purchases. Please contact Jtuck@aegistg.com in regards to any of these matters.

CLOSE